Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response

Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain cancer. Since median overall survival with multimodal standard therapy is only 15 months, there is a clear need for additional effective and long-lasting treatments. Dendritic cell (DC) vaccination is an exper...

ver descrição completa

Detalhes bibliográficos
Principais autores: Dejaegher, Joost, Van Gool, Stefaan, De Vleeschouwer, Steven
Formato: Online Atigo Texto
Idioma:English
Publicado em: Dove Medical Press 2014
Assuntos:
Review
Acesso em linha:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918234/
https://www.ncbi.nlm.nih.gov/pubmed/27471700
http://dx.doi.org/10.2147/ITT.S40121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918234/
https://www.ncbi.nlm.nih.gov/pubmed/27471700
http://dx.doi.org/10.2147/ITT.S40121

Registros relacionados